Hepatocellular Carcinoma (HCC)
This immunohistochemical profile is diagnostic of hepatocellular carcinoma (HCC). The combination of arginase-1 positive and glypican-3 positive with negative cytokeratins (CK7, CK20), negative HepPar-1, and negative PAX8 strongly indicates hepatocellular differentiation rather than cholangiocarcinoma or metastatic disease.
Interpretation of the Immunohistochemical Panel
Positive Markers Supporting HCC:
Arginase-1 positivity: This is the most specific marker for hepatocellular differentiation in your panel. According to the most recent EASL guidelines, arginase-1 is one of the key immunohistochemical markers indicative of hepatocellular differentiation 1. Research demonstrates that arginase-1 has higher sensitivity (84%) and specificity (96%) for HCC diagnosis compared to HepPar-1 2, and importantly, it is never positive in cholangiocarcinoma or most metastatic adenocarcinomas 3.
Glypican-3 positivity: This marker is helpful for differentiating HCC from high-grade dysplastic nodules and benign lesions 4, 1. The 2025 EASL guidelines specifically mention glypican-3 as a marker associated with malignancy in hepatocellular lesions 1.
Negative Markers and Their Significance:
CK7 and CK20 negative: This pattern effectively rules out cholangiocarcinoma, which characteristically shows CK7 positivity 5. The French AFEF guidelines emphasize that cholangiocarcinoma typically demonstrates a CK7+/CK20- profile 5.
HepPar-1 negative: While this may seem contradictory, HepPar-1 can be negative in poorly differentiated HCC 5. The 2024 AFEF guidelines specifically note that HepPar-1 may be negative depending on HCC differentiation and subtype 5. Research confirms that HepPar-1 has lower sensitivity (70%) compared to arginase-1 (84%) for HCC diagnosis 2.
PAX8 negative: This excludes renal cell carcinoma metastasis and other PAX8-expressing tumors.
Clinical Algorithm for This Profile
When you encounter Arginase-1(+) / Glypican-3(+) / CK7(-) / HepPar-1(-) pattern:
- Diagnose as HCC - particularly if poorly differentiated
- Consider the degree of differentiation - HepPar-1 negativity suggests moderate to poor differentiation 6
- Correlate with imaging - look for arterial hypervascularity with venous washout 4
- Assess background liver - evaluate for cirrhosis or chronic liver disease 1
Important Caveats
Why is HepPar-1 Negative?
The negative HepPar-1 in your case is not unusual for poorly differentiated HCC. Research shows that the positive rate for HepPar-1 decreases significantly in poorly differentiated HCC compared to well- or moderately-differentiated tumors 6. The 2024 AFEF guidelines explicitly acknowledge that HepPar-1 can be negative in certain HCC subtypes 5.
Diagnostic Certainty
The combination of arginase-1 and glypican-3 positivity provides near-definitive diagnosis. Studies demonstrate that when using a panel approach, the combination of these markers achieves 100% specificity for HCC when properly interpreted 6. The specificity of arginase-1 alone reaches 96-100% in distinguishing HCC from metastatic carcinoma and cholangiocarcinoma 2, 3.
Differential Diagnosis Excluded:
- Cholangiocarcinoma: Ruled out by CK7 negativity and arginase-1 positivity
- Metastatic adenocarcinoma: Ruled out by arginase-1 positivity (only 2.6% of metastases show any arginase-1 staining) 2
- Renal cell carcinoma: Ruled out by PAX8 negativity
Next Steps in Management
Based on the 2025 EASL guidelines 1:
- Obtain non-tumoral liver tissue if not already done to assess for cirrhosis and fibrosis stage
- Complete staging workup with dynamic CT or MRI to evaluate tumor extent, vascular invasion, and extrahepatic spread
- Assess liver function using Child-Pugh scoring
- Evaluate for portal hypertension with upper endoscopy for varices
- Measure alpha-fetoprotein levels
This immunoprofile represents HCC with moderate to poor differentiation, and the patient should be managed according to HCC treatment algorithms rather than cholangiocarcinoma or metastatic disease protocols.